Contact Us    |      Join    |

"The Voice of Oncology in Massachusetts"

FDA Approved AstraZeneca's Imfinzi (durvalumab) Plus Chemotherapy for Adult Patients With Primary Advanced or Recurrent Endometrial Cancer That is Mismatch Repair Deficient (dMMR)

June 17, 2024 10:48 AM | Katy Monaco (Administrator)

AstraZeneca’s Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).

The approval by the Food and Drug Administration (FDA) was based on the results of a prespecified exploratory subgroup analysis by MMR status in the DUO-E Phase III trial. Results from DUO-E were published in the Journal of Clinical Oncology.

Read More.


860 Winter Street, Waltham, MA, 02451


tel: 781.434.7329

Massachusetts Society of Clinical Oncologists ©2024

Powered by Wild Apricot Membership Software